Several clinical trials and meta-analyses have demonstrated that, independent of cancer type, patients with low TS expression in tumor tissue have longer overall survival and higher sensitivity to 5-FU-based chemotherapy than those with higher TS expression levels [35,36,37,38,39]. This evidence concerns the gene TYMS and neoplasm.